MarketScreener Strategies Monte Rosa Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX 03:29:44 03/09/26 am AEST			5-day change	1st Jan Change
14.04 ^USD	-1.85%		-1.88%	-10.01%

24/08	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
24/08	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI